TG Therapeutics sees FY24 BRIUMVI U.S. revenue target $300M-$305M
The Fly

TG Therapeutics sees FY24 BRIUMVI U.S. revenue target $300M-$305M

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024, prior guidance of $290 to $300 million for full year 2024.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App